<DOC>
	<DOCNO>NCT00000952</DOCNO>
	<brief_summary>The study examine safety effectiveness ritonavir ( anti-HIV drug ) , alone combination anti-HIV drug , HIV-positive child 2 year age . This study also determine effective dos ritonavir future pediatric HIV study . Infants infect HIV mother experience fast disease progression adult old child . Treatment anti-HIV drug administer early age may slow disease progression infant population .</brief_summary>
	<brief_title>A Study Ritonavir ( Anti-HIV Drug ) HIV-Positive Infants Children</brief_title>
	<detailed_description>As group , vertically infected child experience rapid disease progression child infect old age adult . The early administration potent antiretroviral regimen might significantly impact course vertical HIV-1 infection . Infants child stratify age , representative developmental difference relate drug metabolism ( Group I : least 6 month - 2 year , Group II : 3-6 month , Group IIIA : 1 month - 10 week , IIIB : 1 month - le 3 month ) . Within age group two possible dosage cohort . All age group enrol simultaneously dosage Cohort I , initial drug dosage . Progression Cohort II ( high low drug dosage ) decide accord safety , tolerance viral load Cohort I . All therapy Group I/II , whether Cohort I II , introduce follow : single dose ritonavir Day 0 , ritonavir monotherapy Day 7 AM combination therapy Day 7 PM Week 104 . All therapy Group IIIA &amp; IIIB , whether Cohort I II , introduce follow : single dose ritonavir Day 0 AM transition combination therapy Day 0 PM Week 104 . NOTE : Progression combination therapy Group IIIA infants dependent upon result single-dose ritonavir pharmacokinetics ( PK ) . If patient long least presumed HIV-infected , he/she discontinue study . Replacement infant , receive single dose ritonavir , acquire Group IIIB infant ; new infant either presumed HIV infect already show HIV-infected . Clinical evaluation conduct blood urine sample collect regularly treatment period order quantify HIV-1 level determine body chemistry . Pharmacokinetic study require additional blood sample Week 16 . [ AS PER AMENDMENT 6/30/98 : Pharmacokinetics data Cohort I show propose Cohort II start dose low . The dose Cohort II increase . All subject Groups I , II , III begin combination therapy Day 0 increase dose . ] [ AS PER AMENDMENT 3/13/00 : The study extend additional 104 week , provide patient 's viral load undetectable ( 400 copies/ml ) end initial study period . While treatment extension , patient must continue current schedule study drug administration completion study visit . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are HIVpositive . ( Infants 3 month old presumed HIVpositive eligible participate singledose phase study . ) Are age 4 week 2 year ( consent parent guardian require ) . Exclusion Criteria Children eligible study : Have opportunistic ( AIDSrelated ) infection within 2 month study entry . Are allergic 3TC and/or ZDV . Have receive antiHIV drug 6 12 week . Have infection require treatment . Are experience waste ( significant weight loss ) . Have malignancy ( cancer ) . Have certain immune disease , feed tube , HIVrelated encephalopathy ( degenerative disease brain ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>